Bi-specific antibody therapy for the treatment of cancer.
Bi-specific antibodies (BsAbs) combine immune cell activation with tumor cell recognition as a result of which tumor cells are killed by pre-defined effector cells. In this review a brief introduction to monoclonal antibodies will precede a more in-depth presentation of the current status of BsAb therapy for cancer. Target molecules and effector mechanisms aimed at tumor cells or aimed at tumor vasculature, and the application of recombinant DNA technology in the construction of antibodies, will be discussed. The lessons learned from the last decade will be discussed in consideration of the potential future development of BsAbs for cancer therapy.
Groningen University Institute for Drug Exploration, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
S
S
Withoff
W
W
Helfrich
L F
LF
de Leij
G
G
Molema
D000818:Animals; D018033:Antibodies, Bispecific / Q000737:chemistry / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000737:chemistry / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000098:blood supply / Q000276:immunology / Q000628:therapy*; D011961:Receptors, Fc / Q000378:metabolism; D011994:Recombinant Proteins / Q000737:chemistry / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D011961:Receptors, Fc; D011994:Recombinant Proteins